Faricimab · intravitreal injection
Injections & Implants
Approved uses
Neovascular (wet) age-related macular degeneration and diabetic macular edema
nAMD: 6 mg (0.05 mL of 120 mg/mL) by intravitreal injection every 4 weeks for the first 4 doses, then 6 mg at Weeks 28 and 44, Weeks 24, 36 and 48, or Weeks 20, 28, 36 and 44, based on OCT and visual acuity. DME: 6 mg every 4 weeks for at least 4 doses, then, if edema resolves based on CST, the interval may be extended in up to 4 week increments or reduced in up to 8 week increments based on CST and visual acuity; or every 4 weeks for the first 6 doses, then every 8 weeks.
Dual VEGF-A and angiopoietin-2 inhibition, which is what allows the extended interval
Macular edema following retinal vein occlusion
6 mg (0.05 mL of 120 mg/mL) intravitreally every 4 weeks
Contraindications
- Ocular or periocular infection
- Active intraocular inflammation
- Known hypersensitivity to faricimab or any of the excipients in VABYSMO
Intravitreal injection, 6 mg (0.05 mL of 120 mg/mL) in a single-dose prefilled syringe or single-dose vial, one per pack
Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD, DME, and RVO. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD, DME, and RVO has yet to be established.
Warnings & Precautions
- Endophthalmitis and retinal detachments: Intravitreal injections, including VABYSMO, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection techniques must always be used. Instruct patients to report any signs or symptoms suggestive of endophthalmitis or retinal detachment without delay.
- Increase in intraocular pressure: Transient increases in IOP have been seen within 60 minutes of intravitreal injection, including with VABYSMO. IOP and the perfusion of the optic nerve head should be monitored and managed appropriately.
- Thromboembolic events: Although there was a low rate of arterial thromboembolic events (ATEs) in the VABYSMO clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors.
- Retinal vasculitis and/or retinal vascular occlusion: Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with VABYSMO. Discontinue treatment in patients who develop these events. Instruct patients to report any change in vision without delay.
Common Side Effects
The most common adverse reactions (≥ 5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%).
Pregnancy: No adequate and well-controlled studies in pregnant women. VABYSMO given to pregnant monkeys throughout organogenesis increased the incidence of abortions at IV doses 158 times the human exposure (based on Cmax) of the maximum recommended human dose. Based on mechanism, there is a potential risk to female reproductive capacity and to embryo-fetal development. VABYSMO should not be used during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus. Females of reproductive potential should use effective contraception prior to the initial dose, during treatment and for at least 3 months following the last dose.
Lactation: No information on the presence of faricimab in human milk, the effects on the breastfed infant, or the effects on milk production.
The safety and efficacy of VABYSMO in pediatric patients have not been established.